Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

InMed Pharmaceuticals Inc.

NASDAQ: MTRI · Life Sciences · 12 alerts · CIK 1728328

Share price
$19.87Close, Nov 16
Market cap
$109M
Shares outstanding
5.49MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All InMed Pharmaceuticals Inc. filings on SEC EDGAR ↗

7:03 AM ET 8-K
M&A Deal

InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.

InMed Pharmaceuticals Inc. (now renamed Mentari Therapeutics, Inc.) completed its previously announced business combination with private Delaware corporation Mentari Therapeutics on November 6, 2026. This filing provides the required historical financial statements and management's discussion for the acquired Mentari entity for the period ended September 30, 2026. The combined company now trades on Nasdaq under the ticker 'MTRI'.

Counterparty
Mentari Therapeutics, Inc.
4:46 PM ET 8-K
M&A Deal

InMed Pharmaceuticals Signs $490M M&A Deal with Mentari Therapeutics, Inc.

InMed Pharmaceuticals Inc. (renamed Mentari Therapeutics, Inc.) completed its business combination with private Delaware corporation Mentari Therapeutics, Inc. on November 6, 2026. The transaction included a pre-closing financing that raised $490 million in aggregate gross proceeds. The combined company will focus on developing therapies for migraine prevention and is led by the Mentari management team.

Value
$490M
Counterparty
Mentari Therapeutics, Inc.
8:05 AM ET 8-K
M&A Deal

InMed Pharmaceuticals Signs $490M M&A Deal with InMed Pharmaceuticals Inc.

Mentari Therapeutics completed its merger with InMed Pharmaceuticals Inc. and began trading on Nasdaq under the ticker 'MTRI'. In connection with the closing, the company completed $490 million in private placement financings to fund its pipeline of migraine prevention biologics, including MT-001 and MT-002.

Value
$490M
Counterparty
InMed Pharmaceuticals Inc.
4:47 PM ET 8-K
M&A Deal

InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.

InMed Pharmaceuticals provided a status update on its pending merger with Mentari Therapeutics, which is expected to close in Q4 2026. Mentari has announced private placements totaling $490 million to support operations through 2029, and InMed shareholders will vote on the transaction at a meeting on November 4, 2026.

Counterparty
Mentari Therapeutics, Inc.

“We are approaching an important milestone in our proposed merger with Mentari Therapeutics, with our annual general and special meeting scheduled for November 4, 2026. Our focus remains on completing the transaction, which we believe provides shareholders with an opportunity to participate in the development of Mentari's migraine prevention pipeline.”

Eric A. Adams, InMed President and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.